Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140766 | 0.96 | PLD1 (0.47) | PLD1KDM4ECRBNSMN1; SMN2GRIN2D | |
| Hydrochloric Acid SCHEMBL3827230 | 0.94 | PLD1 (0.46) | PLD1KDM4ECRBNSMN1; SMN2GRIN2D | |
| SCHEMBL27850842 | 0.86 | KCNH2 (0.42) | PLD1KDM4ECRBNSMN1; SMN2GRIN2D | |
| SCHEMBL14500987 | 0.82 | SMN1; SMN2 (0.42) | PLD1KDM4ECRBNSMN1; SMN2GRIN2D | |
| SCHEMBL30657008 | 0.76 | KDM4E (0.40) | PLD1KDM4ECRBNSMN1; SMN2POLB | |
| SCHEMBL27735766 | 0.75 | PLD1 (0.35) | PLD1KDM4ECRBNSMN1; SMN2GRIN2D | |
| SCHEMBL27508033 | 0.72 | PLD1 (0.46) | PLD1KDM4ECRBNSMN1; SMN2GRIN2D | |
| SCHEMBL6499166 | 0.71 | PLD1 (0.44) | PLD1KDM4ECRBNSMN1; SMN2GRIN2D | |
| SCHEMBL16637698 | 0.71 | PLD1 (0.44) | PLD1KDM4ECRBNSMN1; SMN2GRIN2D | |
| SCHEMBL30565007 | 0.71 | PLD1 (0.44) | PLD1KDM4ECRBNSMN1; SMN2GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815562-B2 | REACTION OF NITROHALOGENS WITH ANILINES, A BASE AND A CATALYST, HYDROGENATION, | BAYER AKTIENGESELLSCHAFT (DE) | 2004-11-09 | — | — | US | claimed |
| US-20040143138-A1 | Process for the preparation of nitrodiphenylamines | LANXESS DEUTSCHLAND GMBH (DE) | 2004-07-22 | — | — | US | claimed |
| US-6815562-B2 | REACTION OF NITROHALOGENS WITH ANILINES, A BASE AND A CATALYST, HYDROGENATION, | BAYER AKTIENGESELLSCHAFT (DE) | 2004-11-09 | — | — | US | disclosed |
| US-20040143138-A1 | Process for the preparation of nitrodiphenylamines | LANXESS DEUTSCHLAND GMBH (DE) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143138-A1 | Process for the preparation of nitrodiphenylamines | HNMT, PNMT, NNMT | PLD1 3036/4885KDM4E 1382/4885CRBN 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.